Understanding the Diagnostic Potential of Epitranscriptomic Changes in Cancer

Lin Cheng^*
*Correspondence: Lin Cheng, Department of Cancer Research, Zhejiang University, China, Email:

Introduction

Epitranscriptomics, the study of RNA modifications, has emerged as a promising field in cancer research due to its potential to reveal novel molecular mechanisms underlying tumorigenesis and progression. These RNA modifications, including methylation, pseudouridination, and acetylation, are crucial for regulating RNA stability, splicing, translation, and decay. In cancer, alterations in the epitranscriptome have been linked to various hallmarks of cancer, such as uncontrolled cell proliferation, evasion of apoptosis, and metastasis. Unlike genetic mutations that alter the DNA sequence, epitranscriptomic modifications represent a reversible layer of regulation that can modulate gene expression without changing the genetic code. This makes epitranscriptomics a promising avenue for cancer diagnostics, as these modifications can be detected in bodily fluids such as blood or urine, providing a non-invasive means of cancer detection and monitoring. Additionally, the dynamic nature of RNA modifications means they could potentially serve as biomarkers for early cancer detection, prognosis, and response to treatment [1].

Recent advances in high-throughput sequencing technologies, such as RNA sequencing and mass spectrometry, have enabled the global mapping of RNA modifications across different types of cancer. These technologies have uncovered a wide variety of RNA modifications that differ significantly between cancerous and normal tissues. For example, N6-methyladenosine (m6A) is the most abundant internal modification found in Messenger RNA (mRNA) and has been shown to regulate key processes such as RNA splicing, export, and translation. Dysregulation of m6A modifications is associated with several cancers, including lung, breast, and liver cancers. Other modifications, such as 5-methylcytosine (m5C) and pseudouridine (Ψ), have also been implicated in cancer progression. These modifications can alter the behavior of oncogenes and tumor suppressor genes, thereby contributing to the pathogenesis of cancer. The ability to detect these modifications through novel epitranscriptomic profiling techniques opens new possibilities for developing biomarkers that could improve cancer diagnosis and treatment monitoring. Identifying specific RNA modification patterns in cancer patients could allow for more accurate and early detection, providing a clear advantage over traditional diagnostic methods that rely on tissue biopsy or imaging [2].

Description

One of the most studied RNA modifications in cancer is m6A, which plays a pivotal role in regulating mRNA metabolism, stability, and translation. In recent years, substantial evidence has highlighted its involvement in cancer development and progression. Dysregulated m6A methylation can affect the expression of genes involved in cell cycle regulation, apoptosis, and metastasis. For instance, overexpression of m6A methyltransferases such as METTL3 has been observed in several cancers, where it promotes the stability of mRNAs encoding pro-oncogenic factors, such as c-Myc and Cyclin D1. Conversely, loss of m6A demethylases or methyltransferases can lead to reduced m6A levels, contributing to tumorigenesis by stabilizing mRNA transcripts that should otherwise be degraded. The diagnostic potential of m6A lies in its ability to serve as a molecular signature for cancer. Changes in m6A modification patterns can be detected through RNA sequencing technologies, and these changes can be used to identify specific types of cancer or predict disease prognosis. Moreover, because m6A modifications are reversible, they offer a dynamic means of monitoring cancer progression and therapeutic responses, providing real-time biomarkers for treatment efficacy [3].

Another significant RNA modification that has shown promise in cancer diagnostics is pseudouridine (Ψ), which affects the stability and translation efficiency of RNA. Pseudouridine is catalyzed by a family of enzymes known as pseudouridine synthases, and it can be found in both Ribosomal RNA (rRNA) and messenger RNA (mRNA). In cancer, altered levels of pseudouridine have been observed, and its presence in mRNA is thought to enhance translation and stability, thereby promoting tumor growth. Furthermore, pseudouridine modifications have been linked to chemoresistance, as they can influence the translation of key proteins involved in drug metabolism and resistance pathways. Recent studies have shown that pseudouridine levels can be used as a biomarker for assessing cancer treatment efficacy, particularly in cancers that are resistant to conventional chemotherapy. Detecting pseudouridine modifications through advanced RNA sequencing techniques may offer a non-invasive method for monitoring treatment responses and disease relapse. Moreover, pseudouridine-based biomarkers could help identify cancers that are more likely to be resistant to certain therapies, allowing clinicians to tailor treatments to individual patients’ needs [4].

In addition to m6A and pseudouridine, other RNA modifications such as 5-methylcytosine (m5C) have also gained attention in cancer research. m5C modifications are primarily found in non-coding RNAs, including transfer RNAs (tRNA) and long non-coding RNAs (lncRNAs), and have been implicated in gene regulation and cellular processes that are disrupted in cancer. The role of m5C in regulating gene expression and cellular responses to stress makes it a valuable candidate for cancer diagnosis and therapy. Altered m5C levels have been linked to various cancers, including glioblastomas and hematological malignancies, where they may affect the stability and function of non-coding RNAs involved in tumor suppression and metastasis. Techniques to map m5C modifications and other non-coding RNA modifications are still in their infancy, but the growing interest in these modifications suggests that they could be incorporated into diagnostic platforms in the future. By combining the detection of multiple RNA modifications, such as m6A, pseudouridine, and m5C, researchers may be able to develop a comprehensive epitranscriptomic profiling tool that can be used for early cancer detection, prognostic assessments, and therapeutic decision-making [5].

Conclusion

Epitranscriptomics is rapidly evolving as a promising frontier in cancer diagnostics, offering new insights into the molecular mechanisms driving cancer progression. RNA modifications such as m6A, pseudouridine, and 5-methylcytosine are increasingly recognized for their roles in regulating gene expression, tumorigenesis, and response to therapy. By profiling these modifications, researchers are uncovering novel biomarkers that could revolutionize cancer detection and treatment. The ability to detect these modifications in non-invasive samples, such as blood or urine, provides an exciting opportunity for early cancer detection, as well as monitoring treatment responses and predicting patient outcomes. Additionally, the reversible nature of RNA modifications means that they could serve as dynamic biomarkers, allowing for real-time monitoring of cancer progression and therapeutic efficacy. While there are still challenges in mapping and understanding the full spectrum of RNA modifications in cancer, the advances in sequencing technologies and bioinformatics tools are rapidly overcoming these barriers. As our understanding of the epitranscriptome grows, it is likely that epitranscriptomic changes will become an integral part of the cancer diagnostic toolkit, offering new hope for personalized and precise cancer care.

References

1.  Li, S., M-Y. Sun and X. Su. "MiR-885-5p promotes gastric cancer proliferation and invasion through regulating YPEL1." Eur Rev Med Pharmacol Sci 23 (2019).

Google Scholar Cross Ref Indexed at

2. Cheng, Hao, Feiwu Long, Mukesh Jaiswar and Lie Yang, et al. "Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: a meta-analysis." Sci Rep 5 (2015): 1-7.

Google Scholar Cross Ref Indexed at